{
  "id": "589a246d78275d0c4a000033",
  "type": "yesno",
  "question": "Is apremilast effective for psoriasis?",
  "ideal_answer": "Yes, apremilast is effective for treatment of psoriasis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27376729",
    "http://www.ncbi.nlm.nih.gov/pubmed/26923915",
    "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
    "http://www.ncbi.nlm.nih.gov/pubmed/22712800",
    "http://www.ncbi.nlm.nih.gov/pubmed/26243735",
    "http://www.ncbi.nlm.nih.gov/pubmed/26644232",
    "http://www.ncbi.nlm.nih.gov/pubmed/26806620",
    "http://www.ncbi.nlm.nih.gov/pubmed/26549249",
    "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
    "http://www.ncbi.nlm.nih.gov/pubmed/23663752",
    "http://www.ncbi.nlm.nih.gov/pubmed/24595547",
    "http://www.ncbi.nlm.nih.gov/pubmed/26954311",
    "http://www.ncbi.nlm.nih.gov/pubmed/26357944",
    "http://www.ncbi.nlm.nih.gov/pubmed/20419594",
    "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
    "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
    "http://www.ncbi.nlm.nih.gov/pubmed/23569359",
    "http://www.ncbi.nlm.nih.gov/pubmed/26892034",
    "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
    "http://www.ncbi.nlm.nih.gov/pubmed/27538241",
    "http://www.ncbi.nlm.nih.gov/pubmed/26660203",
    "http://www.ncbi.nlm.nih.gov/pubmed/26820148",
    "http://www.ncbi.nlm.nih.gov/pubmed/26837052",
    "http://www.ncbi.nlm.nih.gov/pubmed/27021239",
    "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
    "http://www.ncbi.nlm.nih.gov/pubmed/26792812"
  ],
  "snippets": [
    {
      "text": "CONCLUSION: Apremilast reduces the severity of nail/scalp psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26549249",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Apremilast demonstrated clinically meaningful improvements in psoriatic arthritis and psoriasis at week 16; sustained improvements were seen with continued treatment through 52\u2005weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26792812",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In those that involved doses of 30 mg twice daily, a significantly greater percentage of patients receiving apremilast (28.8% to 40.9%) compared with placebo (5.3% to 5.8%) achieved at least 75% improvement from baseline in Psoriasis Area and Severity Index score at 16 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis. At this time, apremilast should be reserved for patients unable to take disease-modifying antirheumatic drugs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "More recently, three larger double-blinded, and randomized multicenter studies demonstrate that apremilast is efficacious in the treatment of psoriasis and PsA, with significantly higher numbers of apremilast-treated patients achieving endpoints of a 75% reduction compared to baseline in Psoriasis Area and Severity Index (PASI-75) or American College of Rheumatology-20 scores, relative to placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No new significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period.Data were limited to 52 weeks and may not generalize to nonplaque psoriasis.Apremilast was effective in moderate to severe plaque psoriasis.<CopyrightInformation>Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production.Assess apremilast efficacy and safety in moderate to severe plaque psoriasis.Phase II, 12-week, multicenter, double-blind, placebo-controlled, parallel-group, dose-comparison study of 259 subjects randomized 1 : 1 : 1 to placebo, apremilast 20 mg QD or apremilast 20 mg BID.More subjects receiving apremilast 20 mg BID achieved \u2265 75% reduction in Psoriasis Area and Severity Index (PASI-75) vs. placebo (24.4% vs. 10.3%; P = 0.023)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production.Apremilasts effect on patient-reported outcomes (PROs) in patients with moderate to severe psoriasis was evaluated in a phase IIb randomized, controlled trial (NCT00773734).In this 16-week, placebo-controlled study, 352 patients with moderate to severe plaque psoriasis received placebo or apremilast (10, 20, or 30 mg BID)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although further longer-term and comparative efficacy and tolerability data would be beneficial, the current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "More recently, three larger double-blinded, and randomized multicenter studies demonstrate that apremilast is efficacious in the treatment of psoriasis and PsA, with significantly higher numbers of apremilast-treated patients achieving endpoints of a 75% reduction compared to baseline in Psoriasis Area and Severity Index (PASI-75) or American College of Rheumatology-20 scores, relative to placebo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23569359",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No deaths or opportunistic infections were reported.Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis.<CopyrightInformation>\u00a9 2012 The Authors",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, GlaxoSmithKline plc is developing 256066, an inhaled formulation of a PDE4 inhibitor that has demonstrated efficacy in trials in asthma, and apremilast from Celgene Corp has been reported to be effective for the treatment of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20419594",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although further longer-term and comparative efficacy and tolerability data would be beneficial, the current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26220911",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No new significant adverse events emerged with continued apremilast exposure versus the placebo-controlled period.Data were limited to 52 weeks and may not generalize to nonplaque psoriasis.Apremilast was effective in moderate to severe plaque psoriasis.<CopyrightInformation>Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</C",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several drug peculiarities, such as the low frequency of adverse events and the oral route of administration, make apremilast an innovative treatment for moderate-to-severe psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243735",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two new oral medications, apremilast and tofacitinib, have been developed for their immunomodulatory properties, and their potential efficacy in treating psoriasis is being evaluated.We reviewed phase III randomized, placebo-controlled clinical trial results for apremilast and tofacitinib for efficacy and safety in psoriasis.Psoriasis Area and Severity Index (PASI) 75 after 16 weeks for apremilast was between 28.8% and 33.1%.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast was effective in moderate to severe plaque psoriasis..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089047",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both new oral medications, apremilast and tofacitinib, appear to be effective in treating psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast was effective in the treatment of moderate-to-severe plaque psoriasis over 52\u00a0weeks..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357944",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast is an effective and well-tolerated option in treating moderate-to-severe plaque psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27376729",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast has a novel mechanism of action and is safe and effective for the management of psoriasis and psoriatic arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast 20 mg BID for 12 weeks was effective and well tolerated in subjects with moderate to severe plaque psoriasis..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast for the treatment of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26243735",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27021239",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:8893",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011565"
  ],
  "exact_answer": "Yes"
}